

HSHS Wisconsin Clinical Research Institute – Pediatric - Active Study List

| Protocol | Sponsor | NCT Number | Disease Site | Title |
|------------|---------|-----------------------------|---|---|
| ACNS1422 | COG-L | NCT02724579 | Brain | A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients |
| ALTE2031 | COG-L | NCT04089358 | Cancer Control-Other | StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors |
| APEC14B1 | COG-L | NCT02402244 | Cancer Control-Other | The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study |
| DCP-001 | DCP | | Cancer Control-Other | Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) |
| EAQ202 | ECOG-A | NCT05108298 | Cancer Control-Other | Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials |
| AREN03B2 | COG-L | NCT00898365 | Kidney (Renal) | Renal Tumors Classification, Biology, and Banking Study |
| AREN1721 | COG-AYA | NCT03595124 | Kidney (Renal) | A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups |
| ALTE03N1 | COG-L | NCT00082745 | Late Effects | Key Adverse Events after Childhood Cancer |
| ALTE05N1 | COG-L | NCT00736749 | Late Effects | Umbrella Long-Term Follow-Up Protocol |
| ALTE07C1 | COG-L | NCT00772200 | Late Effects | Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer |
| AALL1631 | COG-L | NCT03007147 | Leukemia-Acute Lymphocytic Leukemia (ALL) | International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones. |
| AALL1731 | COG-L | NCT03914625 | Leukemia-Acute Lymphocytic Leukemia (ALL) | A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy) |
| AALL1732 | COG-L | NCT03959085 | Leukemia-Acute Lymphocytic Leukemia (ALL) | A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy |
| ACCL20N1CD | COG-L | NCT04928599 | Leukemia-Acute Lymphocytic Leukemia (ALL) | Financial Distress during Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States |
| ALTE1631 | COG-L | NCT03223753 | Leukemia-Acute Lymphocytic Leukemia (ALL) | A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia |
| AAML1831 | COG-L | NCT04293562 | Leukemia-Acute Myelogenic Leukemia (AML) | A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations |

HSHS Wisconsin Clinical Research Institute – Pediatric - Active Study List

| Protocol | Sponsor | NCT Number | Disease Site | Title |
|----------|---------|-----------------------------|------------------------|---|
| ACCL21C2 | COG-L | NCT05228275 | Multiple Disease Sites | Prospective Cohort Study to Evaluate Immunologic Response Following COVID-19 Vaccination in Children, Adolescents and Young Adults with Cancer |
| AGCT1531 | COG-AYA | NCT03067181 | Multiple Disease Sites | A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors |
| ANBL1531 | COG-L | NCT03126916 | Neuroblastoma | A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) |
| AGCT1532 | COG-AYA | NCT02582697 | Solid Tumor-Other | A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Germ Cell Tumors |